PLIITH Biotechnology

PLIITH Biotechnology is a clinical-stage biopharmaceutical company headquartered in Hangzhou, China, focused on developing innovative small-molecule therapies for metabolic diseases. The company specifically targets conditions with high unmet medical needs, including metabolic-associated steatohepatitis (MASH), obesity, and type 2 diabetes. Its lead program, PT-101, is a highly selective thyroid hormone receptor beta (THR-beta) agonist that aims to treat MASH by improving hepatic lipid metabolism and reducing inflammation. Additionally, PLIITH is advancing a pipeline of oral small-molecule multi-receptor agonists, such as GLP-1R and GIPR dual agonists, to provide convenient and effective treatments for weight management and glycemic control. The leadership team comprises industry veterans with extensive experience in global pharmaceutical R&D, particularly in metabolic health.